NHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics for HLBS Disorders (R33 CT Required)

This funding opportunity supports Phase I investigator-initiated single-site or multi-site clinical trials for diagnostic and/or therapeutic interventions for heart, lung, blood, and sleep disorders in adults and children. It is limited to clinical trials, including bridging studies, and does not accept Phase II or III trials, observational studies that are not clinical trials, mechanistic human studies, or animal studies. Applicants may be nonprofits, universities, governments, small businesses, for-profit organizations, faith-based or community-based organizations, and some other U.S. or foreign-related organizations, but non-domestic foreign organizations are not eligible to apply. Application budgets should not exceed $1,515,000 in direct costs per year, the project period can be up to 3 years, and no cost sharing is required. The number of awards depends on NIH appropriations and the number of meritorious applications.

✳ AI-generated summary — verify against the announcement

• Health
• Research & Discovery
• Patients & People with Health Conditions
• Researchers & Scholars
• Biomedical & Disease Research

• ✓ City or township governments
• ✓ County governments
• ✓ For-profit organizations other than small businesses
• ✓ Independent school districts
• ✓ Native American tribal governments (Federally recognized)
• ✓ Native American tribal organizations (other than Federally recognized)
• ✓ Nonprofits with 501(c)(3) status (other than higher education)
• ✓ Nonprofits without 501(c)(3) status (other than higher education)
• ✓ Others
• ✓ Private institutions of higher education
• ✓ Public and State controlled institutions of higher education
• ✓ Public housing authorities / Indian housing authorities
• ✓ Small businesses
• ✓ Special district governments
• ✓ State governments